I'll be away for the American Society of Human Genetics meeting in Hawaii for most of the next couple of weeks - I'll be covering the conference primarily via Twitter, and you can follow all of the tweets from the conference using the #ASHG2009 hashtag.Genetics bloggers/tweeters should also pencil in the "tweetup" on Thursday 22nd from 4:30 to 5:15 in the ASHG Press Office (Room 318 in the Convention Center), organised by Chris Gunter; anyone interested should RSVP via email. This should be a good chance to put faces to many of the names in your Twitter and RSS feeds.There's a lot of talks I'm looking forward to, but here's one of particular interest to those who follow the personal genomics industry (and a useful counterpoint to my critique of 23andMe's NFL genetics press release yesterday):> Web-based, participant-driven studies yield novel genetic associations for common traits. N. Eriksson1, J. M. Macpherson1, J. Tung1, L. Hon1, B. Naughton1, S. Saxonov1, L. Avey1, A. Wojcicki1, I. Pe'er2, J. Mountain1,3
In a post over a year ago I argued that 23andMe would have an edge over academic researchers when it came to identify the common variants underlying non-clinical but interesting complex traits:> Secondly, even if it proves impossible to compete with academic researchers in the medical genomics space, 23andMe and deCODEme (but not Navigenics) do have a fairly good fall-back position: they can generate information about things that fascinate the public, but are difficult to get funding for in the public arena. I'm talking, of course, about both genealogy/ancestry testing and the genetics of normal variation (e.g. pigmentation, handedness, attached versus detached earlobes, that sort of thing). Genetic genealogy and ancestry testing are huge markets, and 23andMe already seems to do them better than most other companies in the space - certainly their interface is slick, and their investment in this whole-genome analysis of almost 1,000 genetically diverse humans performed by Stanford University researchers demonstrates their commitment to this area. In addition, 23andMe's customer base will give it substantial power to uncover the genetic determinants of many variable traits that would seem trivial to a grant committee, but that customers would pay good money to explore - especially once scans become cheap enough to run on multiple family members.
It's genuinely exciting to see this potential starting to come to fruition. Subscribe to Genetic Future.
Follow Daniel on Twitter.